CDC Expands RSV Vaccine Recommendations for Adults 75 and Older

1. Expanded Recommendations: The CDC has expanded its RSV vaccine recommendations to include all adults aged 75 and older, as well as those between 60 and 74 with heightened RSV risk due to medical conditions.
2. Risk-Based Strategy: The CDC's focus is on a risk-based strategy to increase vaccine uptake, prioritizing older adults at the highest risk of severe RSV illness.
3. Vaccine Efficacy: Moderna's mRESVIA vaccine demonstrated 50% efficacy in preventing RSV over 18 months, while GSK's Arexvy and Pfizer's Abrysvo vaccines showed 78% effectiveness in preventing severe RSV over subsequent seasons.
4. Market Impact: The revised recommendations may reduce the addressable U.S. market for RSV shots in 2024-25 from 93 million to about 55 million.
5. Public Health Concern: RSV is a significant public health concern, leading to a substantial number of hospitalizations and deaths annually in the United States.